title: [Clinical efficacies of inhaled corticosteroids plus theophylline in the treatment of bronchial asthma].
abstract: OBJECTIVE
  To explore the therapeutic efficacies of inhaled corticosteroids (ICS) plus low-dose theophylline for moderate bronchial asthma.
  
  
  METHODS
  A total of 280 patients with moderate bronchial asthma at People's Hospital of Zhengzhou University between January 2011 and December 2011 were recruited and randomized into 2 groups: observation group with inhaled budesonide 400 µg/d plus aminophylline tablet (0.1 g, 3 times/day, oral administration and control group with inhaled budesonide 320 µg/day plus formoterol 9 µg/day. The course of treatment was around 6 months. The forced expiratory volume in one second % predicted (FEV1% predicted), interleukin (IL)-4, IL-5 and IgE of peripheral blood were compared before and after treatment.
  
  
  RESULTS
  Before and 6 months after treatment, the values of FEV1 % predicted, IL-4, IL-5 and IgE for the observed group were 68% ± 6% and 76% ± 6%, (14.5 ± 4.4) and (7.2 ± 2.6) ng/L, (27.4 ± 6.2) and (24.2 ± 5.9) ng/L, (771 ± 130) × 10(3) and(592 ± 104) × 10(3) U/L, respectively, while those for the control group were 66% ± 8% and 77% ± 6%, (13.7 ± 4.3) and (7.7 ± 4.0) ng/L, (26.9 ± 5.8) and (24.6 ± 4.8) ng/L, (752 ± 154) and (604 ± 122) × 10(3) U/L, respectively. There were significant improvements in both groups (all P < 0.05). No differences existed between two groups (all P > 0.05).
  
  
  CONCLUSIONS
  Compared with ICS plus inhaled long-acting β2-agonists (LABA), ICS plus low-dose theophylline shows similar efficacies in the improvement of lung function and the control of airway inflammation for asthmatics.
authors.affiliation: Department of Respiratory and Critical Care Medicine, Zhengzhou University, Zhengzhou, China.
authors.forename: Zhuo-chang
authors.initials: ZC
authors.lastname: Chen
authors.forename: Juan-juan
authors.initials: JJ
authors.lastname: Ding
authors.forename: Hao-yu
authors.initials: HY
authors.lastname: Qian
authors.forename: Xiang-hua
authors.initials: XH
authors.lastname: Lin
authors.forename: Ke-qing
authors.initials: KQ
authors.lastname: Feng
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D000628:Aminophylline / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D000068759:Formoterol Fumarate; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D015848:Interleukin-5 / Q000097:blood; D008297:Male; D008875:Middle Aged; D013806:Theophylline / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D004983:Ethanolamines; C508598:IL4 protein, human; C508599:IL5 protein, human; D015848:Interleukin-5; D015847:Interleukin-4; D000628:Aminophylline; D007073:Immunoglobulin E; D019819:Budesonide; D013806:Theophylline; D000068759:Formoterol Fumarate